SFA Therapeutics Announces FDA Approval To Begin IND Trial

Clinical Trial Examines Human Micro-biome-based Drug SFA002 In Mild to Moderate Plaque Psoriasis PHILADELPHIA, June 29, 2020 -- (Healthcare Sales & Marketing Network) -- SFA Therapeutics, Inc. is pleased to announce that the US FDA has provided approva... Biopharmaceuticals, Dermatology SFA Therapeutics, psoriasis, microbiome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news